- Home
- ESLA vs VERU Comparison
ESLA vs VERU Comparison
Compare ESLA & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESLA | VERU |
|---|---|---|
| Founded | 2021 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.9M | 39.8M |
| IPO Year | N/A | 1990 |
Fundamental Metrics
Financial Performance| Metric | ESLA | VERU |
|---|---|---|
| Price | $1.42 | $2.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $16.00 | ★ $25.00 |
| AVG Volume (30 Days) | 102.0K | ★ 193.6K |
| Earning Date | 02-26-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $2.10 |
| 52 Week High | $3.15 | $14.20 |
Technical Indicators
Market Signals| Indicator | ESLA | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 40.82 | 46.57 |
| Support Level | $1.19 | $2.20 |
| Resistance Level | $1.54 | $2.40 |
| Average True Range (ATR) | 0.16 | 0.16 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 34.43 | 58.97 |
Price Performance
Historical ComparisonAbout ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.